Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: statistical analysis plan for a randomised controlled trial (UPGRADE trial)

BACKGROUND: Approximately 8–15% of patients undergoing bariatric surgery develop symptomatic gallstone disease within 24 months after surgery. Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery. The aim of the UPGRADE...

Descripción completa

Detalles Bibliográficos
Autores principales: Haal, Sylke, Guman, Maimoena S. S., de Brauw, L. Maurits, van Veen, Ruben N., Schouten, Ruben, Fockens, Paul, Gerdes, Victor E. A., Dijkgraaf, Marcel G. W., Voermans, Rogier P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376318/
https://www.ncbi.nlm.nih.gov/pubmed/32703246
http://dx.doi.org/10.1186/s13063-020-04605-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376318/
https://www.ncbi.nlm.nih.gov/pubmed/32703246
http://dx.doi.org/10.1186/s13063-020-04605-7

Ejemplares similares